Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action

We are pleased to be expanding our agreement with KSURF as we move forward with our ongoing COVID-19 development program.